Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).
The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.
Our lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific for PSMA-positive tumours. CB307’s unique format delivers highly potent tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA-positive cancer indications.
Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® platform, which generates fully human VH domains (Humabodies). Humabodies are matured in vivo in the absence of any light-chains and are robust and stable molecules. Humabody VH domains can be easily assembled into multi-specific formats which can access novel biology and deliver superior tumour accumulation and penetration compared to conventional monoclonal antibody-based approaches.
The Humabody platform has received third party validation through its strategic, multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M, and from licensing its first programme for an inflammatory target to Zai Lab in 2018. In 2020 Crescendo entered into a Clinical Development Partnership with Cancer Research UK to progress CB213, a PD-1 x LAG-3 bispecific, into the clinic.
Crescendo is progressing novel Humabody®-based product opportunities, through in-house development and strategic collaborations as well as seeking strategic partners to develop novel Humabody therapeutics leveraging our in-house expertise and our pipeline of Humabody molecules.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $133.79M
Founded date: 2009
Investors 3
Funding Rounds 4
Date | Series | Amount | Investors |
24.07.2023 | - | $32M | Kreos Capi... |
02.05.2018 | Series B | $70M | - |
03.04.2014 | Series A | $3.32M | - |
17.12.2013 | Series A | $28.47M | - |
Mentions in press and media 28
Date | Title | Description | Source |
06.03.2024 | Crescendo Biologics to present at the 2024 AACR Annual Meeti... | - | globenewsw... |
24.07.2023 | Crescendo Biologics secures $32M and announces expansion of ... | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targ... | anderapart... |
11.01.2022 | BioNTech and Crescendo Biologics announce global collaborati... | BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision i... | cambridgen... |
16.09.2021 | Crescendo to Participate in Upcoming Investor Conferences | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targ... | marketscre... |
07.07.2021 | Crescendo to Participate in Upcoming Investor Events | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targ... | marketscre... |
01.06.2021 | Crescendo to participate in upcoming investor conferences | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targ... | marketscre... |
27.02.2019 | Cofinitive shortlisted for International Trade Champion awar... | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards 27-02-2019 C... | cambridgen... |
05.11.2018 | Crescendo Biologics announces early licensing by Takeda | anderapart... | |
05.11.2018 | Regenxbio scores $180M vector deal; Bristol-Myers expan... | → Abeona Therapeutics $ABEO has licensed Regenxbio’s $RGNX NAV AAV9 vector for four diseases:... | endpts.com... |
14.09.2018 | Top scientist Thor Voigt vaults to CMO role at Boehringer ... | Thor Voigt → Boehringer Ingelheim has promoted one of its top scientists to the chief medical... | endpts.com... |
Show more